Author: Kat

通过无柱免疫细胞磁分选工作流程从 TCR α/ß+中分离TCR γ/δ+

近年来 T 细胞受体 (TCR) 细胞疗法因其为癌症和感染性疾病提供一系列可能性的治疗而获得广泛关注。由于γδ T细胞被视为对癌症免疫治疗颇有潜力的区域细胞，基于γδ T细胞的新型免疫疗法正在被大力开发。尽管TCR疗法在研发、生产及临床应用等领域已经取得重大进展，但 TCR细胞疗法的开发在功效及安全性方面仍然面临很多挑战。 MARS® 平台为优化和扩大 γδ T细胞的研发和生产提供了一种简单而又全新的方法和工具，可以帮助TCR 疗法最大化的发挥临床潜力。

TCR γ/δ+ separation from TCR α/ß+ with MARS® Bar

In recent years T cell receptor (TCR) cell therapy has gained popularity due to a range of possible treatments for cancer and some infectious diseases it could provide. Since γδ T-cells constitute promising effector cell compartments for cancer immunotherapy, novel γδ T-cell-based immunotherapies are being developed. Although advancements in TCR engineering, manufacturing, and clinical applications have led to […]

MARS® MAG Premium Line

MARS® MAG Premium Line is a family of cell separation reagent kits launched in collaboration with STEMCELL Technologies. These reagents have been shown to enable fast and easy isolation of many cell types, including granulocytes, NK cells, and plasma cells. With protocols optimized for the MARS instruments, the kits provide an integrated cell isolation solution. This is especially […]

通过MARS®平台分选 CD3- CD56+ NK 细胞

NK细胞是目前肿瘤免疫治疗领域主要的创新目标。开发和改造基于NK细胞的癌症免疫疗法需要清洁且高效的小体积和大规模的细胞分离方法。创新产品MARS®Bar系统为CD56+/CD3-细胞分离提供了新一代大规模、磁分离技术，可以从单采血、全血或骨髓细胞制品中进行分离。

MARS® Ingenuity™ Line of Reagents brochure

MARS® Ingenuity™ Line is a family of cell isolation reagent kits launched in collaboration with GenScript USA Inc. aiming to deliver combined solutions for cell therapy drug development worldwide. The kits include research and cGMP-grade reagents for fast and easy cell isolation supporting the development of CAR-T and other Cell Therapy products on the MARS® […]

MARS® Bar among the Winners of The Scientist’s Top 10 Innovations of 2022

Santa Clara, California – We are thrilled to announce that MARS® Bar is among the Winners of The Scientist’s Top 10 Innovations of 2022! Each year The Scientist highlights the latest and greatest tools, technologies, and techniques to hit the life science landscape.  This year’s crop of entries to The Scientist’s Top 10 Innovations contest […]

从激活血液中高效分离CD34+造血干细胞

近年来，多能造血干细胞（HSC）治疗因其一系列的具有希望的疗效已成为一种流行的技术。广泛的可能性使这种前沿治疗方法成 为现代医学的转折点。该技术面临的其中一个公认的挑战是为移植快速获得足够数量的高纯度的所需细胞类型。目前，耗时的样 品制备步骤和在此过程中大量细胞损失仍然是一个重大的挑战。MARS®平台通过一种简单的方法从激活的血液中分离CD34+细胞，而不需要RBC裂解和密度梯度离心。